Tanovea (rabacfosadine) Solution for Injection Vials

Name: Tanovea (rabacfosadine) Solution for Injection Vials
Brand: Tanovea (rabacfosadine)
SKU: 62778
Availability: OutOfStock
Rating: 0 (0 reviews)

Price range: $ 1,349.99 through $ 3,374.99

(0 customer reviews)

Prescription(s) Required

We’ll collect your pet information to verify this prescription with your veterinarian before shipping. Your prescription order will ship upon veterinarian approval.

This item is specially packaged to remain refrigerated during transit. 1-2 Day Air Refrigerated Shipping Only OR Local Pickup. Does not Qualify for Free Shipping.

STRENGTH/SIZE

QUANTITY

Clear

Categories: Dog Cancer Medications, Dog Immunosuppressives Tag: Cancer Medications Brand: Tanovea (rabacfosadine) Brand: Tanovea (rabacfosadine)

Description

Description

Tanovea® is a promising new anti-cancer drug designed to treat canine lymphoma. Most cancer treatments are initially targeted for human use and then secondarily modified for animals; however, Tanovea® was developed specifically for dogs, heralding a new ear in veterinary research and drug discovery.

Uses

Tanovea® can only be prescribed by a licensed veterinarian since the accurate diagnosis, treatment, and management of side effects are crucial for the drug’s proper use and efficacy. Tanovea® has been demonstrated to be effective against the following diseases in dogs:³

Non-Hodgkin’s lymphoma (NHL)
Canine cutaneous T-cell lymphoma
Spontaneous canine multiple myeloma
Naïve canine multicentric lymphoma
Relapsed canine B-cell lymphoma

For more information please visit: Tanovea (rabacfosadine)

Additional information

Weight	N/A
STRENGTH/SIZE	16.4 mg.
QUANTITY	4 Vials., 10 Vials.
Brand	Tanovea
Administration	Tanovea®, which comes in a concentrated form, is diluted and each dose (1mg/kg) is intravenously infused over a 30-minute period once every three weeks, then repeated up to five times. If adverse reactions are a problem, stepwise dose reduction to 0.8 mg/kg and then to 0.66 mg/kg or a dose delay may be helpful. It is important that the infusion be administered by or under the supervision of a licensed veterinarian experienced in chemotherapy.4 Tanovea® provides a treatment option that differs from other chemotherapeutic drugs since one dose is given every three weeks for a total of five infusions. This is in steep contrast with conventional chemotherapy treatments that require up to 16 weekly visits.5 In addition, Tanovea is thought to be effective for the treatment of recurring lymphoma.6 It has been shown to be effective toward dogs that are new to the drug, have become drug-resistant, and/or are not responding to a standard treatment protocol such as CHOP.6 These findings provide hope and the potential for an extension of your dog’s quality of life.
While using Tanovea®	Before using Tanovea® Read the client information sheet carefully7 and discuss with your veterinarian any concerns that you might have regarding the protocol. Follow the suggestions listed below:4 Tell your veterinarian about all other medications your pet is taking, including prescription drugs, over the counter drugs, heartworm preventatives, flea and tick medications, vitamins and supplements, including herbal medications. Tell your veterinarian about your pet’s previous or current medical conditions. If your dog has pulmonary fibrosis or even has a history of chronic pulmonary disease such as chronic bronchitis, do not use this medication. Use this medication with caution if you have a terrier since these breeds have a potential genetic disposition to develop pulmonary fibrosis. Do not use in West Highland White Terriers, since they do have a genetic predisposition for development of pulmonary fibrosis. Pregnant women, women who may become pregnant, and nursing women should not handle or administer LAVERDIA-CA1 or come in contact with the feces, urine, vomit, or saliva from LAVERDIA-CA1-treated dogs. LAVERDIA-CA1 may cause birth defects and can affect female fertility based on animal studies. Wear protective disposable chemotherapy resistant gloves when handling LAVERDIA-CA1 to avoid exposure to drug. Wear protective disposable chemotherapy resistant gloves to prevent direct contact with moistened, broken, or crushed LAVERDIA-CA1 tablets. Wear protective disposable chemotherapy resistant gloves to prevent contact with feces, urine, vomit, and saliva during treatment and for 3 days after the dog has received the last treatment. Place all waste material in a plastic bag and seal before general disposal. Wash hands immediately and thoroughly with soap and water if contact occurs with the feces, urine, vomit, or saliva from LAVERDIA-CA1 treated dogs. Any items that come in contact with feces, urine, vomit, or saliva should not be washed with other laundry during treatment and for 3 days after the last treatment with LAVERDIA-CA1. Wear protective disposable chemotherapy resistant gloves when handling the dog’s toys, food bowl, and water bowl. Wash food and water bowls separately from other items during treatment and for 3 days after the dog has received the last treatment. If LAVERDIA-CA1 is accidentally ingested, or if there is significant contact with feces, urine, vomit, or saliva of dogs during treatment or within 3 days after the last treatment without proper precautions, seek medical advice immediately. It is important to show the treating physician a copy of the package insert, label, or client information sheet.
Possible Side Effects	Similar to most medications, especially cytotoxic drugs, Tanovea® may cause side effects even if you are using the prescribed dose. The most common side effects include the following:1 Diarrhea Vomiting Loss of appetite Weight loss Lethargy Skin problems: loss of hair, sores, scabs In addition to the side effects listed above, the adverse reactions listed below have also been observed; however, with the exception of pulmonary fibrosis, these reactions resolve spontaneously or with supportive treatment, dose modifications, and/or dose delays.4 Renal: Increased creatinine, blood urea nitrogen, protein, bacteria, and/or pus detected in urine Hepatic: Elevated liver enzymes, elevated bilirubin Cardiorespiratory: Pulmonary fibrosis, aspiration pneumonia, difficult or labored breathing, increased breathing rate, increased heart rate. Hematologic: Reduction in white blood cells and important blood proteins as well as low potassium and phosphate levels Administering Tanovea® has also been associated with more serious and sometimes fatal respiratory complications. Please contact your veterinarian immediately if your pet experiences any of the following symptoms:7 Extreme nausea, vomiting, and diarrhea Refusal to eat for more than 1 day Fever Difficulty breathing Extreme lethargy e instructions given by your veterinarian.
Storage Instructions	Store the bottles at controlled room temperature 20° to 25°C (68° – 77°F).
Interactions	As a “conditionally approved” drug”, the safety and effectiveness of Tanovea® has not been fully evaluated in conjunction with other chemotherapeutic agents or other treatment modalities. In addition, the effect of concomitant medication on metabolism of Tanovea has not been evaluated.4 Although the “client information sheet” distributed by the drug maker does not list drug interactions, the FDA encourages dog owners to work with their veterinarians to report all side effects or possible drug interactions. Please keep a record of all adverse reactions and a list of all drugs or supplements that your dog is taking during the course of Tanovea® treatment. Share these with your veterinarian who will prepare and submit a report to the FDA. This information will be reviewed by the FDA to identify potential safety and effectiveness concerns.1 Drug interactions may change how your pet’s medications work or increase risk for serious side effects, so be observant and report any changes in your dog’s health or behavior to your veterinarian as soon as possible. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.